Loading
A phase 3 trial of Epcoritamab in diffuse large b-cell lymphoma, run by Genmab, active and no longer recruiting.
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China is a phase 3 interventional study registered as NCT07226752 by Genmab, with 72 participants enrolled, started 2022-10-08 and due to reach its primary completion in 2025-10-13. Interventions recorded: Epcoritamab, Investigator's Choice Chemotherapy. Conditions listed: Diffuse Large B-Cell Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares ctDNA-guided escalation and de-escalation in frontline DLBCL, Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/